The FDA does not have sufficient data for systematic oversight and tracking of postmarketing safety issues for drugs it has approved, according to a new report from the Government Accountability Office.
Since fiscal year 2007, drug manufacturers have submitted more than 770 requests for fast-track designation under one of the FDA’s four expedited programs, and the FDA granted about two-thirds of those requests, the GAO found. About one-fourth of the drug